KODKODHealthcare · Biotechnology

KOD Stock Forecast: Kodiak Sciences, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$97
−3.90% on the day

The 7 Wall Street analysts covering Kodiak Sciences, Inc. hold a median 12-month price target of $129 — +32.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 16 Nov 2026 — in the upper half.

Market cap
$6.6B
Ticker Nerd rank
59/ 100
Median analyst target
$129
Analysts covering
7
Revenue$0.0
Operating income−$66.8M
Net income−$65.6M
Free cash flow−$46.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.4%
1M
+12.9%
YTD
+246.2%
1Y
+388.1%
From 52W high
−12.9%
From 52W low
+403.6%
$19
$111
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KOD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kodiak Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
59/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Accruals
89
Value
85
Issuance
70
Revisions
37
Growth
37
Volatility
36
Quality
23
Size
19

Momentum (100): The shares have been drifting up relative to others.

Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (19): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KOD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KOD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Jan 26Apr 26Jul 26Oct 26KODHigh $150Median $129Low $103

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $103Median $129High $150

The green dot is the last close — the median target sits +32.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Nov 2026UBSMaintainsBuy$120 → $150
12 Oct 2026HC Wainwright & Co.MaintainsBuy$96 → $126
12 Oct 2026HC Wainwright & Co.MaintainsBuy—
28 Sept 2026HC Wainwright & Co.MaintainsBuy—
28 Sept 2026HC Wainwright & Co.MaintainsBuy$58 → $96
28 Sept 2026LifeSci CapitalMaintainsOutperform—
28 Sept 2026LifeSci CapitalMaintainsOutperform$85 → $145
28 Sept 2026UBSMaintainsBuy$80 → $120
28 Sept 2026UBSMaintainsBuy—
24 Sept 2026Goldman SachsReinstatesNeutral$36
17 Sept 2026HC Wainwright & Co.ReiteratesBuy$58
17 Sept 2026HC Wainwright & Co.ReiteratesBuy—
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$58
17 Aug 2026HC Wainwright & Co.ReiteratesBuy—
3 Aug 2026JP MorganMaintainsOverweight$56 → $66
3 Aug 2026JP MorganMaintainsOverweight—
11 May 2026Chardan CapitalUpgradeBuy—
11 May 2026Chardan CapitalUpgradeBuy$14 → $61
27 Mar 2026HC Wainwright & Co.ReiteratesBuy—
27 Mar 2026UBSMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KOD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KOD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, Kodiak Sciences, Inc. returned +388.1% against +11.2% for the S&P 500, dividends included.

KOD vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600Jan 26Apr 26Jul 26Oct 26KODS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KOD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Kodiak Sciences, Inc. (KOD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−23.3×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
103.4×

Cheaper than 2% of US stocks

EV / EBITDA
−30.3×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−1360.9%

Higher than 1% of US stocks

Return on assets
−74.6%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kodiak Sciences, Inc. (KOD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kodiak Sciences, Inc. has a market value of $6.6B and an enterprise value of $7.2B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$242.0M.

  • Diluted earnings per share, trailing twelve months: −$4.19.

  • Free cash flow in the twelve months to 30 June 2026: −$159.9M.

  • Shares outstanding: 62.8M.

  • Trailing P/E: −23.3×; forward P/E: −29.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Kodiak Sciences, Inc. employs 144 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

KOD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KODKodiak Sciences, Inc.$6.6B59
ORKAOruka Therapeutics, Inc.$6.6B37
IMVTImmunovant, Inc.$6.7B58
TWSTTwist Bioscience Corp.$6.9B62
IBRXImmunityBio, Inc.$6.3B40
ARWRArrowhead Pharmaceuticals, Inc.$6.2B41
AXSMAxsome Therapeutics, Inc.$7.1B73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kodiak Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KOD news & analysis

Kodiak Sciences Inc. (KOD) Presents at UBS Global Biopharma Conference 2026 Transcript

Seeking Alpha · 17 Nov 2026neutral

Kodiak Sciences CEO and President Victor Perlroth presented at the UBS Global Biopharma Conference 2026. The excerpt provides the conference details and opening remarks, but no further presentation content.

Why it matters — The transcript records a company presentation for KOD watchers, though the provided excerpt contains no substantive business or scientific updates.

Kodiak Sciences: Sticking With Hold As Optimistic Assumptions Are Already Priced In

Seeking Alpha · 13 Nov 2026neutral

Kodiak Sciences has risen 1,857% since a November 2024 Hold upgrade, but the author maintains a Hold, saying the roughly $6.8 billion valuation already reflects optimistic commercial expectations. Zenkuda's multi-indication BLA submission is set to begin in Q4, while competition and the difficulty of switching well-controlled patients may limit uptake.

Why it matters — KOD watchers may weigh the upcoming regulatory process and twice-yearly dosing proposition against the author's concerns about valuation and commercial penetration.

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

Zacks Investment Research · 13 Nov 2026neutral

Kodiak Sciences reported a wider-than-expected third-quarter loss. Positive Phase III results for Zenkuda and progress across its pipeline are supporting upcoming regulatory plans.

Why it matters — KOD watchers may follow how the quarterly loss and pipeline developments shape the company’s regulatory plans.

Kodiak Sciences to Present at Three Upcoming Investor Conferences

PRNewsWire · 11 Nov 2026neutral

Kodiak Sciences announced that Victor Perlroth, M.D., will present at three upcoming investor conferences. The announcement was issued on November 11, 2026.

Why it matters — The presentations provide KOD watchers with scheduled opportunities to hear from a company representative.

FAQ

Frequently asked questions about KOD stock

What is the KOD stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Kodiak Sciences, Inc. have a median 12-month price target of $129, with estimates ranging from $103 to $150. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KOD stock a buy right now?

Of the 7 analysts covering Kodiak Sciences, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kodiak Sciences, Inc. 59 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KOD?

As at 16 Nov 2026, Kodiak Sciences, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will KOD stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +32.7% from the last close, and Ticker Nerd's factor model ranks Kodiak Sciences, Inc. 59 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KOD stock forecast for 2030?

No analyst covering Kodiak Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KOD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $150 over the next 12 months.

How has KOD stock performed over the past year?

Kodiak Sciences, Inc. returned +388.1% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kodiak Sciences, Inc. do?

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases.

What is the latest news on KOD?

The most recent item we track (Seeking Alpha, 17 Nov 2026): "Kodiak Sciences Inc. (KOD) Presents at UBS Global Biopharma Conference 2026 Transcript". Kodiak Sciences CEO and President Victor Perlroth presented at the UBS Global Biopharma Conference 2026. The excerpt provides the conference details and opening remarks, but no further presentation content.

Company

About Kodiak Sciences, Inc.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases. The company works on treatments for conditions that affect the retina and can lead to vision loss, with a portfolio centered on ophthalmology and retinal vascular disorders. Its current programs include late-stage and earlier-stage candidates built around its proprietary Antibody Biopolymer Conjugate platform, which is designed to support the development of next-generation eye medicines. Kodiak Sciences Inc. serves the biopharmaceutical and ophthalmic research markets by advancing specialized therapeutics for diseases such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. Headquartered in Palo Alto, California, and founded in 2009, the company remains focused on researching, developing, and commercializing retina-directed medicines for patients and eye-care specialists.

CEO Dr. Victor Perlroth M.D. · 144 employees · United States · https://kodiak.com